PapersPMID:38563131
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Although the PASI score in the melatonin and rosuvastatin groups compared with placebo decreased, the changes were not significant.”
- Study
- RCT
- Dose studied
- melatonin cream 5.0% (w/w) applied twice a day
- Population
- adults with mild-to-moderate plaque psoriasis; melatonin cream 5% w/w vs placebo cream, applied twice daily for 8 weeks
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults with mild to moderate stable plaque psoriasis (lesion area ≤100 cm2).
- Participants
- 77
- Comparator
- an active treatment / placebo
- Duration
- 60 days
- Endpoints measured
- 21
melatonin